A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03574571|
Recruitment Status : Recruiting
First Posted : July 2, 2018
Last Update Posted : February 21, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: Docetaxel 75 mg/m2 Drug: Docetaxel 60 mg/m2 Drug: Radium-223||Phase 3|
|Study Type :||Interventional|
|Estimated Enrollment :||738 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||This is an open-labeled, randomized, phase III study of docetaxel versus docetaxel in combination with radium-223 in subjects with mCRPC.|
|Masking:||None (Open Label)|
|Official Title:||Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)|
|Actual Study Start Date :||June 19, 2018|
|Estimated Primary Completion Date :||February 1, 2026|
|Estimated Study Completion Date :||February 1, 2026|
Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses. Prednisone will be given at a dose of 5mg orally twice daily.
Drug: Docetaxel 75 mg/m2
Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses.
Experimental: Docetaxel with Radium-223
Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses. Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
Drug: Docetaxel 60 mg/m2
Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses.
Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
- Overall survival [ Time Frame: 2 years ]Overall survival is defined as the time from randomization to death from any cause.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Male|
|Gender Based Eligibility:||Yes|
|Gender Eligibility Description:||Prostate|
|Accepts Healthy Volunteers:||No|
- Willing and able to provide written informed consent (ICF) and HIPAA authorization for the release of personal health information. A signed informed consent must be obtained before screening procedures are performed.
NOTE: HIPAA authorization may be either included in the informed consent or obtained separately.
- Males 18 years of age and above
- Histological or cytological proof of prostate cancer
Documented progressive mCRPC based on at least one of the following criteria:
- PSA progression defined as 25% increase over baseline value with an increase in the absolute value of at least 1.0 ng/mL that is confirmed by another PSA level with a minimum of a 1 week interval and a minimum PSA of 1.0 ng/mL.
- Soft-tissue progression defined as an increase ≥ 20% in the sum of the LD of all target lesions based on the smallest sum LD since treatment started or the appearance of one or more new lesions.
- Progression of bone disease (evaluable disease) or two or more new bone lesions by bone scan.
- Two or more bone lesions
- ECOG 0- 1
Normal organ function with acceptable initial laboratory values within 14 days of randomization:
- Albumin > 30 g/L
- ANC ≥ 1.5 x 10^9/L
- Hemoglobin ≥ 10 g/dL
- Platelet count ≥ 100 x 10^9/L
- Creatinine ≤ 1.5 x the institutional upper limit of normal (ULN)
- Bilirubin ≤ ULN (unless documented Gilbert's disease)
- SGOT (AST) ≤ 1.5 x ULN
- SGPT (ALT) ≤ 1.5 x ULN
- WBC count ≥ 3 x 10^9/L
- Subjects must agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including 30 days after the last dose of study drug. Sperm donation is prohibited during the study and for 30 days after the last dose of study drug. Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent.
- Serum testosterone < 50 ng/dL. Subjects must continue primary androgen deprivation with an LHRH analogue (agonist or antagonist) if they have not undergone orchiectomy.
- All acute toxic effects of any prior treatment have resolved to NCI-CTCAE v4.0 Grade 1 or less.
- Willing and able to comply with the protocol, including follow-up visits and examinations
- Received any other investigational therapeutic agents or other anticancer therapies within 4 weeks prior to randomization.
- Received external beam radiotherapy within the 4 weeks prior to randomization.
- Has an immediate need for external beam radiotherapy.
- Has received any systemic bone-seeking radiopharmaceutical in the past.
- Has received any prostate cancer directed chemotherapy in the castration resistant setting. Subjects who have received up to 6 prior doses of docetaxel in the castration sensitive setting are permitted if they have not experienced disease progression within 36 weeks of last treatment with docetaxel.
Has received four or more systemic anticancer regimens for mCRPC.
- Treatment with docetaxel or abiraterone for non-castrate metastatic disease is permissible and does not count towards the lines of therapy for mCRPC
- A 'line' is a regimen. Combinations of hormones and other types of therapies count as single lines.
- Has known Grade ≥3 docetaxel-related toxicities or docetaxel toxicity related dose interruption or discontinuation.
- Has received blood transfusions or growth factors within the last 4 weeks prior to randomization.
- Symptomatic nodal disease (i.e., scrotal, penile, or leg edema).
- Has visceral metastases with ≥ 3 lung and/or liver metastases or individual lesion ≥2 cm, as assessed by CT scan or MRI of the chest/abdomen/pelvis within the last 8 weeks prior to randomization.
- Symptomatic loco-regional disease that causes ongoing Grade 3 or Grade 4 urinary or rectal symptoms.
- Subjects with a "currently active" second malignancy other than non-melanoma skin cancers or non-invasive bladder cancers or other in-situ or non-invasive malignancies. Subjects are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 3 years.
- Has imminent or established cord compression based on clinical findings and/or MRI.
- Known bone marrow dysplasia
- Has received any of the following in the 4 weeks prior to randomization: 5-alpha-reductase inhibitors, herbal medications, natural hormonally active foods (e.g., phytoestrogens) or other food supplements known to alter PSA in humans
Any other serious illness or medical condition that would, in the opinion of the investigator, make this protocol unreasonably hazardous, including but not limited to:
- Uncontrolled infection
- NYHA III or IV heart failure
- Crohn's disease or those with ulcerative colitis who have not undergone a colectomy
- Known active infection with HIV, Hepatitis B or Hepatitis C
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03574571
|Contact: Michael Morris, MDfirstname.lastname@example.org|
|Contact: Josef Fox, MD||212-639-7371|
|Principal Investigator:||Michael Morris, MD||Memorial Sloan Kettering Cancer Center|
|Responsible Party:||Memorial Sloan Kettering Cancer Center|
|Other Study ID Numbers:||
2018-002944-10 ( EudraCT Number )
|First Posted:||July 2, 2018 Key Record Dates|
|Last Update Posted:||February 21, 2023|
|Last Verified:||February 2023|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Genital Neoplasms, Male
Neoplasms by Site
Molecular Mechanisms of Pharmacological Action